Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03438565 · ClinicalTrials.gov registry record
SURE 18 Registry -Asahi Chikai Black 18 in LVO Stroke
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 100
- Enrollment target
NCT03438565: Completed study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT03438565 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03438565 has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
The objective of this study is to obtain post market data on the Asahi Chikai Black 18 neurovascular guidewire in the treatment of intracranial large vessel occlusive stroke. This will be compared to a historical control that will include the prior 50 consecutive patients fitting the same selection criteria.
Primary Outcome
Time from guide catheter placement within the target ICA to clot engagement
Interventions
- DEVICE Asahi Chikai Black 18 neurovascular guidewire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-03-18 |
| Est. Completion | 2020-02-01 |
What the finished NCT03438565 record still lists
NCT03438565 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Asahi Chikai Black 18 neurovascular guidewire is the first listed.
NCT03438565 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03438565 about?
NCT03438565 is a clinical study titled "SURE 18 Registry -Asahi Chikai Black 18 in LVO Stroke". The objective of this study is to obtain post market data on the Asahi Chikai Black 18 neurovascular guidewire in the treatment of intracranial large vessel occlusive stroke. This will be compared to a historical control that will include the prior 50 consecutive patients fitting the same selection ...
What is the current status of trial NCT03438565?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2018-03-18. Estimated completion is 2020-02-01.
What interventions are being tested in trial NCT03438565?
The interventions under investigation include: Asahi Chikai Black 18 neurovascular guidewire (DEVICE).
Who is sponsoring clinical trial NCT03438565?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI